Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Breast Neoplasms 48Lung Neoplasms 34Ovarian Neoplasms 33Fallopian Tube Neoplasms 22Carcinoma, Ovarian Epithelial 21Adenocarcinoma of Lung 16Unspecified Adult Solid Tumor, Protocol Specific 13Brenner Tumor 11Adenocarcinoma, Bronchiolo-Alveolar 11Head and Neck Neoplasms 10Breast Neoplasms, Male 10Neoplasm Metastasis 9Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasms 7Esophageal Neoplasms 7Endometrial Neoplasms 7Adenocarcinoma Of Esophagus 6Urinary Bladder Neoplasms 5Oropharyngeal Neoplasms 5Melanoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Peritoneal Neoplasms 4Mouth Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

trastuzumab biosimilar HLX02 1Trastuzumab 1Taxes 1Radiotherapy 1Radiation 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Bladder Urothelial Carcinoma × Paclitaxel × Clear all
NCT00238420 2022-07-19

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 10 charts
Genitourinary

Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡